Humanetics Corporation

About:

clinical stage pharmaceutical company.

Website: http://www.humaneticscorp.com

Top Investors: National Institutes of Health, U.S. Department of Defense, National Heart, Lung and Blood Institute, Regenerative Medicine Minnesota

Description:

Humanetics is a privately held, clinical stage pharmaceutical company located in the Minneapolis metropolitan area. The Company was founded in 1988 and is engaged in developing and commercializing products to enhance human health and wellbeing. Humanetics entered the field of radiation modulators in 2003, through a cooperative research program with the Armed Forces Radiobiology Research Institute (AFRRI). Humanetics began working with AFRRI to test an array of drug candidates using their highly developed capabilities. From this program, BIO 300 emerged as a lead candidate and the underlying technology was in-licensed from AFRRI to Humanetics. In the ensuing years, the Company has progressed this program into multiple clinical uses with a primary focus on improving treatment of solid tumor cancers.

Total Funding Amount:

$9.2M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Minneapolis, Minnesota, United States

Founded Date:

1988-01-01

Founders:

David Mindell, Ronald Zenk

Number of Employees:

11-50

Last Funding Date:

2023-10-24

IPO Status:

Private

Industries:

© 2025 bioDAO.ai